NCTF® & NANOSOFT™ NEW REVOLUTION IN AESTHETIC MEDICINE

"THE NANOSOFT™ WILL IMPROVE
PATIENTS EXPERIENCE " Dr. Riekie SMIT

IDEAL FOR DELICATE AREAS
NEAR PAINLESS
MINIMAL BRUISING
QUICK RESULTS
LESS INVASIVE



NEXT APPOINTMENTS

1/ Date time
2/ Date time

ASK YOUR PRACTITIONER FOR ADVICE

BEAUTY IS AN ART, WE MADE IT A SCIENCE

교

To discover the entire FILLMED product range please visit www.fillmed.com

Laboratoires FILL-MED - Registered trademark 2-4, rue de Lisbonne - 75008 Paris - Tel. : +33 (0)1 88 40 12 80

NANOSOFT[™] is a medical device to be used by authorized practitioners only. NCTF® 135 and NCTF® 135 HA are injectable medical devices. If any adverse event occurs, please inform your doctor. Each distributor or each subsidiary is responsible for making this document compliant to its local regulations. Materiovigilance (notification of an adverse event) contact: vigilance(affitImed.com



FRAGILE SKIN ZONES

The signs of ageing that most women worry about all appear in certain areas: crow's feet, eye contour, lip contour, neck.^[1] However, the skin in these areas is very thin and marks easily, making them very tricky to treat.



THE MAIN WOMEN'S CONCERNS

48% DARK CIRCLES 35% CROW'S FEET

35% LINES AROUND THE MOUTH AND LIPS

27% NECK (FIRMNESS & ELASTICITY)

EYE CONTOUR - PERIORAL AREA NECK & DECOLLETAGE







Continuous movement



Difficult to target efficiently

Laboratoires FILLMED, specialists in aesthetic medical procedures for forty years, is launching NANOSOFTTM, a new and safe medical device to inject NCTF® with minimal pain and bruising. It's ideal for treating the face, especially the delicate eye and lip areas, neck and décolletage.

NCTF® & NANOSOFT™ FOR BEAUTIFUL SKIN

Comprising hyaluronic acid and revitalizing ingredients, NCTF® 135 HA is a hydration booster providing the essential ingredients for skin health. Injecting it using the NANOSOFT™ is extremely innovative: it guarantees maximum efficacy, safety and patient satisfaction.





360° SKIN QUALITY

+144%	RADIANCE ^[2] (observed in 88% of cases)
+132%	HYDRATION ⁽²⁾ (observed in 83% of cases)
+52%	HOMOGENEITY ^[3]
-43%	FINE LINES(3)
-59%	PORES SIZE ⁽³⁾

[2] Study of the effects of the repeated intradermal injections of NCTF® 135 HA on the consequences of the cutaneous ageing of the face, 2011. Open, multicentric and prospective study conducted in 20 to 25 centres. 40 patients included [51,5 years old on average], 2 of them left the study. 3 sessions spaced out by 15 days and 2 sessions by 30 days. [3] Clinical evaluation of anti-ageing efficacy of mesotherapy with NCTF® 135 HA on healthy volunteers, 2014. Open, single-centre and prospective study, 20 patients included [49,25 years old on average], 2 of them left the study. 3 sessions spaced out by 15 days and 2 sessions by 30 days.

NEW SOFT INJECTION

1/ WHY THE DOCTOR NEEDS TO TARGET THE DERMIS?

The intradermal layer is fundamental when revitalising the skin. It is where the fibroblasts are, which are responsible for collagen and elastin production. The advantage of the NANOSOFTTM is that it guarantees a controlled and standardized injection depth into the dermis minimizing pain and improving safety.

2/ WHAT HAPPENS IN A SESSION?

The practitioner cleanses and disinfects the patient's skin. The product is injected into the upper dermis and gentle pressure applied to the treated area: a tiny papula forms. The same procedure is repeated every centimetre



to cover the full area. In the eye area, the injection is given along the upper and lower eyelids and on the crow's feet. On the neck and décolletage, the product is injected along the wrinkles' path.

3/ IS IT FOR YOU?

The NANOSOFTTM is around three times smaller than a normal injection needle. It improves patient comfort, minimises the risk of bruising and makes the rest of the aesthetic protocol easier: small papules immediately form and quickly spread the product around the dermis. Within 24 hours, the honeycomb pattern fades to reveal hydrated, plumped, smooth skin.





ΔETER 1 SESSION OF NCTE® 135 HΔ

(1) Arcane study 2018 – 8,646 women (aged 18-75)